Cell and gene therapy (CGT) automation specialist Limula has been granted a key US patent for its next-gen CGT manufacturing technology.
The newly granted patent adds to the company's growing portfolio of intellectual property, covering core innovations on its platform.
Limula's technology is designed to automate and streamline the production of cell therapies through a singular device, which integrates multiple functionalities.
The device is capable of both cell incubation and processing, which prevents the transfer of cells between modules — eliminating the need for multiple tools.
It also reduces a user's operational footprint, as well as consumable costs and the need for manual interventions.
Notably, Limula created the technology to pave the way to point-of-care manufacturing, which would allow the production of CGTs in a hospital setting.
"This IP protection strengthens Limula's competitive position in the cell and gene therapy market," noted Luc Henry, CEO and co-founder of Limula.
"We anticipate product launch soon, and we're continuing to engage with hospitals, biotechs, CDMOs and pharmaceutical partners worldwide, facilitating their inclusion on our early access programme,"
"As we continue to build our IP portfolio, we will progress towards making these personalised treatments scalable and accessible to more patients," he concluded.
Limula is currently looking for partners interested in testing its technology through its early access programme — with more details available on the company's website.